An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 18 Apr 2017 Planned End Date changed from 1 Jun 2018 to 30 Jul 2018.
- 18 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 30 Jul 2018.
- 21 Mar 2017 Planned number of patients changed from 500 to 550.